Cinacalcet Tablet, Film Coated
Product Images NDC 67877-505

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 67877-505). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cinacalcet 30mg 30tab

Cinacalcet Tablets 30 mg film-coated oral tablets label by Ascend Laboratories, LLC. The label specifies 30 tablets per container with storage instructions and manufacturer details for Alkem Laboratories, Ltd., India. It includes the NDC number 67877-503-30 and warnings for prescription use only.*

FDA Label Image

Cinacalcet 60mg 30tab

Cinacalcet Tablets 60 mg film-coated oral tablets label from Ascend Laboratories, LLC. The label indicates the strength as 60 mg and package count as 30 tablets. Includes NDC 67877-504-30 and manufacturer information, storage instructions, and a barcode.*

FDA Label Image

Cinacalcet 90mg 30tab

Label for Cinacalcet Tablets 90 mg film-coated oral tablets from Ascend Laboratories, LLC. The label states it contains 30 tablets with prescription only status. Storage instructions indicate 25°C with permitted excursions to 30°C. Manufacturer is Alkem Laboratories Ltd., India, and distributor is Ascend Laboratories, Parsippany, NJ. A barcode and NDC 67877-505-30 are shown.*

FDA Label Image

Cinacalcet-fig3 (Cinacalcet Fig3)

A line graph depicting calcium levels (mg/dL) over time in weeks during titration and maintenance phases for patients with parathyroid carcinoma. The X-axis represents weeks from baseline through 80 weeks, and the Y-axis shows calcium concentration ranging from 8 to 16 mg/dL. Data points include error bars indicating variability.*

FDA Label Image

Cinacalcet-fig4.jpg (Cinacalcet Fig4)

A line graph showing serum calcium levels (mg/dL) over time (weeks) during titration and maintenance phases for a treatment, with calcium levels generally decreasing and stabilizing after titration. The x-axis represents weeks, and the y-axis shows calcium concentration, including the number of subjects with intractable pHPT at each time point.*

FDA Label Image

Cinacalcet-figure-1.jpg (Cinacalcet Figure 1)

A line graph depicting mean intact parathyroid hormone (iPTH) levels (pg/mL) over 26 weeks from pooled phase 3 studies. Two curves compare the effects of Cinacalcet versus placebo, showing iPTH values decreasing steadily with Cinacalcet treatment, while placebo values remain relatively stable.*

FDA Label Image

Cinacalcet-figure-2.jpg (Cinacalcet Figure 2)

A line graph titled 'Figure 2. Mean (SE) Ca x P Values (Pooled Phase 3 Studies)' comparing calcium-phosphorus product levels (mg/dL) over 26 weeks between placebo and Cinacalcet groups. The x-axis shows weeks (0 to 26), and the y-axis shows Ca x P values from 0 to 70. The Cinacalcet group shows a decrease in values over time, while the placebo group remains relatively stable.*

FDA Label Image

Cinacalcet-str (Cinacalcet Str)

Chemical structure of the active ingredient Cinacalcet hydrochloride shown as a molecular diagram, featuring aromatic rings, a trifluoromethyl group, and other molecular components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.